Patients with renal abnormalities requiring modification of radiation field (pelvic kidney, renal transplant, etc.)
Renal insufficiency with serum creatinine > .
Renal insufficiency as indicated by a creatinine level > times ULN
Active myeloma as defined as the presence of calcium, renal failure, anemia and bone (CRAB) criteria: hypercalcemia, renal insufficiency, anemia and/or bone disease
Patients with renal insufficiency with an estimated glomerular filtration (EGF) <=  are excluded, due to they will not be able to undergo gadolinium enhance MRI.
Renal failure; exception: if GFR (glomerular filtration rate) is > %, a patient with renal failure can be included in the study
Imperative indication for nephron sparing surgery \r\n* Baseline chronic kidney disease (CKD) (stage , glomerular filtration rate [GFR]  <  ml/min/.m^), or anatomically or functional solitary kidney (defined by renal scintigraphy of contralateral renal unit with < % function) or bilateral synchronous disease); and \r\n* Radius Exophytic/endophytic properties, Nearness of the tumor to the collecting system or sinus, Anterior/posterior, and Location relative to polar lines (RENAL) score >=  or proximity to renal hilum (defined as  <  mm away from at least  renal hilar vessels-the main artery/vein or first order branches); and\r\n* Radical nephrectomy would lead to severe CKD (stage , GFR <  ml/min/.m^)
History of any renal calculi or hyperoxaluria or any other preexisting renal disorder
Creatinine > . or history of renal disease preventing use of ZA
Renal insufficiency, defined as serum creatinine > . mg/dL
Significant renal pathology defined as:\r\n* Estimated creatinine clearance (CrCl) <  mL/min (using Cockcroft-Gault formula based on actual body weight) and serum creatinine > . mg/dL; OR\r\n* Active, untreated SSc renal crisis at the time of enrollment; presence of nephrotic range proteinuria (defined as >= . gms/ hours, or protein:creatinine ratio >= .), active urinary sediment, urinary RBCs >  per HPF, or red cell casts require further investigation by a nephrologist to rule out glomerulonephritis, overlap syndromes, or other causes of renal disease in all subjects; subjects with glomerulonephritis or overlap syndromes will be excluded
Documented hepatic insufficiency or renal failure
Renal
Renal insufficiency, with creatinine greater than . mg/mL
Biopsy proven renal neoplasm\r\n* All histology of renal cancers are included, including oncocytoma
Any medical history, concurrent disease or concomitant medication which could reasonably predispose the patient to renal insufficiency while on study treatment
Patients with non-organ confined renal masses (invading renal vein, inferior vena cava, peri-renal tissue, ipsilateral adrenal gland, or metastasis)
Severe renal disease (creatinine > x  normal for age)
Renal insufficiency or serum creatinine >. X ULN at screening.
Subjects with renal dysfunction defined as (a) Chronic renal failure requiring renal replacement therapy (RRT), or (b) Acute renal failure with onset of oliguria (urine output < . ml/kg/hr) >  hours prior to first dose of study drug whether receiving RRT or not
Renal insufficiency as indicated by a creatinine level >  x the ULN.
Renal
Patients with renal failure (GFR <  mL/min) are excluded
Chronic renal disease / failure
Renal insufficiency creatinine > . mg/dl
Renal
Severe liver or renal insufficiency
Renal insufficiency (serum creatinine >  mg/dL).
Renal insufficiency or serum creatinine above the normal reference range
Renal insufficiency (creatinine >= . mg/dl)
History of renal disease or current evidence of renal disease
Acute renal failure
Renal:
Patients with a history of renal disease
Acute renal failure
Acute or chronic severe renal insufficiency (glomoerular filtration rate < milliliters [mL]/minute/. square meters) or acute renal insufficiency of any severity due to the hepato-renal syndrome.
Patients with history of renal or hepatic insufficiency.
Patients with solitary kidneys, bilateral renal tumors, compromised renal function (baseline creatinine > .)
Renal insufficiency, defined as creatinine level greater than the upper limit of normal for age
Patient has no unstable renal function, defined as a change in estimated glomerular filtration rate (eGFR) (calculated with the MDRD equation) of > % for patients with mild and moderate renal impaired or as a change in eGFR > % for patients with severe renal impaired, from screening to enrollment.
Patients with severe renal insufficiency, defined and confirmed by an estimated creatinine clearance equal or lower than  mL/min, per institutional laboratory.
Acute or chronic renal insufficiency with creatinine clearance <  mL/min, drawn within  days of consent
Chronic renal failure in renal replacement therapy
Renal insufficiency defined as estimated glomerular filtration rate of <  or hepatic insufficiency defined as transaminitis or hyperbilirubinemia of > . times the highest normal value
Renal failure
Arterial insufficiency
Patients with normal renal function according to MD Anderson testing standards and no prior renal disease
Subjects with renal insufficiency (estimated creatinine clearance less than  mL/minute at baseline or likely to require dialysis during the study)
Patients >=  years without underlying renal insufficiency get GFR tested within  months of the exam.
Patients <  years without underlying renal insufficiency do not require an GFR calculation.
Patients >=  years with known underlying renal insufficiency get GFR tested within  month of the exam.
Patients <  years with known renal insufficiency get GFR tested within  month of the exam.
Participants with renal insufficiency or failure, as determined by a point of care renal function blood test.
EXCLUSION - PATIENT: Known or suspected renal insufficiency, rendering the participant unable to safely receive intravenous contrast based on institutional clinical protocol; renal insufficiency for the purposes of exclusion includes any of the following:\r\n* Known history of end stage renal disease with estimated glomerular filtration rate (eGFR) <  mL/min/. m^\r\n* Point of care (POC) measure of creatinine clearance (eGFR) prior to obtaining the MRI < ; we will perform this POC test as needed per institutional policy for routine MRI if: (a) answered yes to any of the Choyke question AND no creatinine result is available in the optical mark recognition (OMR) software within  days of the MRI exam, regardless of patient age, or (b) the patient is >  years old, or (c) the patient is on hydroxyurea
Patients with renal failure are eligible; however, patients with pre-existing renal insufficiency will likely have further compromise in renal function and may require dialysis
History of renal disease
Individuals with uncontrolled renal insufficiency or renal failure
Individuals with uncontrolled renal insufficiency or renal failure
Individuals with end stage renal disease, known glomerular filtration rate (GFR) < , current or anticipated dialysis or transplant within the next two years will be excluded; a history of renal transplant is not an exclusion per se if patient does not meet stated renal criteria
Renal insufficiency (i.e., serum creatinine outside of normal limits)
Renal insufficiency with plasma creatinine > .
Renal insufficiency with recent (<  month old) creatinine > .
Women with renal failure or insufficiency
Renal insufficiency with recent (<  month old) creatinine > . mg/dL
Participants with renal insufficiency or failure, as determined by a point of care renal function blood test
Contraindications for MRI with contrast or PET/CT including:\r\n* Cardiac pacemaker, implanted cardiac defibrillator, pacing wires, internal electrodes\r\n* Aneurysm clips\r\n* Cochlear, otologic, or other ear implant\r\n* Tissue expander\r\n* Swan-Ganz or thermodilution\r\n* Moderate renal insufficiency (estimated glomerular filtration rate [GFR] less than  mL/min/. m^) to end stage renal disease (estimated GFR less than  mL/min/. m^ or a serum creatinine more than  mg/dL), who are not on dialysis, and patients with renal failure on chronic dialysis\r\n* Severe claustrophobia
Acute renal dysfunction due to the hepato-renal syndrome or in the perioperative liver transplantation period
Exposure to gadolinium-based contrast agents increases the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or severe renal dysfunction; therefore, patients with the following conditions are excluded from the study:\r\n* Acute or chronic severe renal insufficiency (glomerular filtration rate <  mL/min/. m^)\r\n* Acute renal dysfunction due to the hepato-renal syndrome or in the perioperative liver transplantation period
In order to identify subjects at risk for the development of NSF, the American College of Radiology (http://acr.org) recommends obtaining a medical history and a glomerular filtration rate (GFR) assessment within six weeks of MR imaging in the following patients: \r\n* Renal disease (including solitary kidney, renal transplant, renal tumor)\r\n* Age > \r\n* History of hypertension\r\n* History of diabetes\r\n* History of severe hepatic disease/liver transplant/pending liver transplant
Normal creatinine and estimated glomerular filtration rate (GFR) within  days under the following circumstances:\r\n* Had abnormal creatinine in the last  days\r\n* Are over  years of age\r\n* Has received chemotherapy within the past  days\r\n* Has diabetes, human immunodeficiency virus (HIV), renal disease or history (hx) of renal cancer
Severe renal insufficiency (GFR ? ).
History of renal insufficiency (only for MRI contrast administration)
Renal insufficiency
Patients with inadequate renal function (creatinine >= . times upper limit of normal) or acute or chronic renal insufficiency (glomerular filtration rate <  ml/min)
Patients with renal insufficiency such that they cannot get intravenous contrast as part of screening or follow-up
